Exelixis, Inc. (EXEL) · Sep 11, 2026 · Other events
FDA review delayed — PDUFA date moved to March 3, 2027 from December 3, 2026
Exelixis’ colorectal-cancer drug review moves to March 2027 after the FDA requests and accepts major safety and efficacy updates.
The key change is a three-month regulatory delay. The FDA moved the action date for zanzalintinib in combination with atezolizumab to March 3, 2027. 〔0〕 The prior standing date was December 3, 2026, so the filing pushes out a potentially important approval catalyst by one quarter.
| Item | Prior expectation | New information |
|---|---|---|
| FDA action date | December 3, 2026 | March 3, 2027 (Filing) |
| Review status | Standard review | Review extended three months (Filing) |
The delay reflects additional FDA scrutiny, not a routine scheduling change. Exelixis says it submitted updated safety and efficacy data in response to an FDA information request, and the agency deemed that submission a major amendment. 〔1〕 That raises uncertainty around the application relative to the previously expected review timeline, even though the filing does not disclose a specific safety concern or indicate that the application is headed for rejection.
Versus what was already expected, this is a modest negative read. The direction of the event is clear: the approval decision and any launch-related contribution arrive later than the market’s prior timetable. The filing contains no new efficacy result, approval, or commercial guidance to offset the timing setback, so the net takeaway is a delayed catalyst rather than a changed clinical thesis.
FDA decision on zanzalintinib, March 3, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!